FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q90471578> ?p ?o ?g. }

• Q90471578 description "2019 թվականի սեպտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
• Q90471578 description "article scientifique publié en 2019" @default.
• Q90471578 description "artículu científicu espublizáu en setiembre de 2019" @default.
• Q90471578 description "im September 2019 veröffentlichter wissenschaftlicher Artikel" @default.
• Q90471578 description "scientific article published on 10 September 2019" @default.
• Q90471578 description "wetenschappelijk artikel" @default.
• Q90471578 description "наукова стаття, опублікована 10 вересня 2019" @default.
• Q90471578 name "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N" @default.
• Q90471578 name "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N" @default.
• Q90471578 type Item @default.
• Q90471578 label "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N" @default.
• Q90471578 label "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N" @default.
• Q90471578 prefLabel "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N" @default.
• Q90471578 prefLabel "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N" @default.
• Q90471578 P1433 Q90471578-6BF4A4F8-2891-4DB8-A849-70AE5C9ADFA3 @default.
• Q90471578 P1476 Q90471578-4A09D8B0-2A24-40A7-A693-0D514D39156C @default.
• Q90471578 P2093 Q90471578-169907B6-D251-4781-ACF0-EB76B3D82494 @default.
• Q90471578 P2093 Q90471578-186654A5-4C5A-4E4E-9744-FD7FB8A3EF78 @default.
• Q90471578 P2093 Q90471578-1E2ECB1E-B8A2-4309-B543-3EA349C89FBC @default.
• Q90471578 P2093 Q90471578-2D446169-76CE-415C-A0E6-40FE76FC00FE @default.
• Q90471578 P2093 Q90471578-C5488097-0783-4A65-8E5F-182D099E5CA1 @default.
• Q90471578 P275 Q90471578-0A9A64F9-F790-48DD-8910-2B261D11FCC7 @default.
• Q90471578 P2860 Q90471578-0197C9EC-45D4-43C0-9E1F-CCBA19113B2A @default.
• Q90471578 P2860 Q90471578-028016D9-A1E5-42A1-B7E7-5C5FA59B695A @default.
• Q90471578 P2860 Q90471578-070F3321-A982-4682-8FFB-0395747E2FA6 @default.
• Q90471578 P2860 Q90471578-0D924B50-8C2F-41A9-8460-A81BD1BC7FEF @default.
• Q90471578 P2860 Q90471578-248BD630-3429-4CA0-BA80-A4889378AA9F @default.
• Q90471578 P2860 Q90471578-28AE26EA-A0A3-41E8-AD92-6344AF0757E4 @default.
• Q90471578 P2860 Q90471578-38D00CB3-DA2E-4FF7-8C74-00F3648377F8 @default.
• Q90471578 P2860 Q90471578-393BC8BA-EA10-4AC8-9DF5-225766B903F5 @default.
• Q90471578 P2860 Q90471578-3DF9B5B5-8585-4A20-B9B2-374B23C068E9 @default.
• Q90471578 P2860 Q90471578-4AB3CDBE-4617-48A4-BE7D-44B0A39F7BA7 @default.
• Q90471578 P2860 Q90471578-4D2A0910-D8CB-4231-9EED-DAFFA1360459 @default.
• Q90471578 P2860 Q90471578-5598CAF0-81E7-48C0-9DEF-633EDD1954A8 @default.
• Q90471578 P2860 Q90471578-5F36E384-FD48-4F60-B0CC-CBAE8C91CB77 @default.
• Q90471578 P2860 Q90471578-63513874-868C-4EB6-8D82-1F1CDDAA4ACA @default.
• Q90471578 P2860 Q90471578-6A22C5FB-59E2-4510-9975-706D9A50FD1D @default.
• Q90471578 P2860 Q90471578-7133B7EF-81CD-4C86-BA65-18558F32672A @default.
• Q90471578 P2860 Q90471578-71574B16-7B4E-4622-A3CE-D9E7026CB2E7 @default.
• Q90471578 P2860 Q90471578-78375633-8017-4120-91B2-83CE11A74BC4 @default.
• Q90471578 P2860 Q90471578-7F41A625-C422-478C-868B-9AE8D2A8DA78 @default.
• Q90471578 P2860 Q90471578-9D2E549E-BC63-45AD-8372-DC51412525CB @default.
• Q90471578 P2860 Q90471578-A7343DE2-8051-449A-9B6B-84717261411B @default.
• Q90471578 P2860 Q90471578-A73CD31D-4553-41D1-A95A-4025D91FF525 @default.
• Q90471578 P2860 Q90471578-B319594A-8603-47E5-B622-1DDF64DF0ED6 @default.
• Q90471578 P2860 Q90471578-B52CE40A-8C5A-4D28-9446-164E268ADA95 @default.
• Q90471578 P2860 Q90471578-B78363B4-9664-4D66-9A5E-E37B4232AC92 @default.
• Q90471578 P2860 Q90471578-C2C40A8C-375D-4FED-8734-D1260128E9FC @default.
• Q90471578 P2860 Q90471578-CA81758D-C20A-4746-B8A3-E15BDE781684 @default.
• Q90471578 P2860 Q90471578-D64074A4-693D-4B64-B13C-8C5BEC2918F4 @default.
• Q90471578 P2860 Q90471578-D81E0CB4-C4CA-4BA1-84A2-D11557385361 @default.
• Q90471578 P2860 Q90471578-D95751A9-7A66-4FF1-AD69-1B2911293151 @default.
• Q90471578 P2860 Q90471578-DC12DC84-C201-448B-9FE5-603D435CAD7B @default.
• Q90471578 P2860 Q90471578-DC882029-69AD-44A3-9116-F00023BDE9A6 @default.
• Q90471578 P2860 Q90471578-DC8EE776-7D78-4969-901C-D9DBD8C7AD46 @default.
• Q90471578 P2860 Q90471578-E468AF2F-82BE-4DFA-9744-C51CDA40746D @default.
• Q90471578 P2860 Q90471578-E52B49DA-3796-4F4B-A82E-4583545ED403 @default.
• Q90471578 P2860 Q90471578-EA0C0155-B261-4245-BFC1-CC4AD38CB8D4 @default.
• Q90471578 P2860 Q90471578-EA1DC1BF-0A20-438E-81B8-016B4C025425 @default.
• Q90471578 P2860 Q90471578-F6A07007-3E40-47FF-92D4-FD5228052D44 @default.
• Q90471578 P304 Q90471578-01F61994-39F1-4215-AB2D-5E18B0345EFA @default.
• Q90471578 P31 Q90471578-A1B9FEDA-A8E9-4002-BC10-812550777E83 @default.
• Q90471578 P31 Q90471578-de0bff29-28fd-4d65-9b72-84f5319f4093 @default.
• Q90471578 P356 Q90471578-7572F2F5-4D92-4C39-9DDF-84B31029D730 @default.
• Q90471578 P478 Q90471578-0E9E11F7-B369-4D8A-99A3-C6E1FEDD4718 @default.
• Q90471578 P50 Q90471578-2ED8F277-2CBB-4FEB-927C-E82C3EC9A6E9 @default.
• Q90471578 P577 Q90471578-91628C46-0E1B-4F89-80E4-F12CD7E5DA85 @default.
• Q90471578 P6216 Q90471578-EA399100-83D9-42BD-80CA-46FF1AB14CF4 @default.
• Q90471578 P698 Q90471578-71CCB3F3-FF3F-488C-BC5A-94E3D0B3F66D @default.
• Q90471578 P921 Q90471578-508EFDDA-05AF-4C15-BC09-A1081FEA8AED @default.
• Q90471578 P921 Q90471578-E41F8193-AA7A-486F-A1D9-0D168205AA63 @default.
• Q90471578 P932 Q90471578-2BC557BE-81B9-41CA-8EF5-2CD0A33A83D1 @default.
• Q90471578 P356 2546161 @default.
• Q90471578 P698 31583255 @default.
• Q90471578 P1433 Q26841936 @default.
• Q90471578 P1476 "Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials" @default.
• Q90471578 P2093 "Fan Bai" @default.
• Q90471578 P2093 "Gang Gang Li" @default.
• Q90471578 P2093 "Qingmin Liu" @default.
• Q90471578 P2093 "Ruilian Li" @default.
• Q90471578 P2093 "Xinwu Niu" @default.
• Q90471578 P275 Q20007257 @default.
• Q90471578 P2860 Q26991871 @default.
• Q90471578 P2860 Q28280453 @default.
• Q90471578 P2860 Q28280465 @default.
• Q90471578 P2860 Q30248242 @default.
• Q90471578 P2860 Q34575053 @default.
• Q90471578 P2860 Q34969188 @default.
• Q90471578 P2860 Q35612972 @default.
• Q90471578 P2860 Q36913621 @default.
• Q90471578 P2860 Q38094925 @default.
• Q90471578 P2860 Q38510678 @default.
• Q90471578 P2860 Q38558536 @default.
• Q90471578 P2860 Q38558538 @default.
• Q90471578 P2860 Q38812025 @default.
• Q90471578 P2860 Q39684745 @default.
• Q90471578 P2860 Q40973506 @default.
• Q90471578 P2860 Q41118310 @default.
• Q90471578 P2860 Q41185712 @default.
• Q90471578 P2860 Q43470214 @default.

• next